EA033057B1 - Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека - Google Patents

Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека

Info

Publication number
EA033057B1
EA033057B1 EA201890361A EA201890361A EA033057B1 EA 033057 B1 EA033057 B1 EA 033057B1 EA 201890361 A EA201890361 A EA 201890361A EA 201890361 A EA201890361 A EA 201890361A EA 033057 B1 EA033057 B1 EA 033057B1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
alkoxy
ris
compounds
tetrahydroisoquinolin
Prior art date
Application number
EA201890361A
Other languages
English (en)
Other versions
EA201890361A1 (ru
Inventor
Кайл Дж. Истман
Джон Ф. Кадоу
Кайли И. Парселла
Б. Нарасимхулу Наиду
Тао Ван
Чживэй Инь
Чжонсин Чзан
Original Assignee
ВАЙВ ХЕЛТКЕР ЮКей (№ 5) ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56851651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA033057(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ВАЙВ ХЕЛТКЕР ЮКей (№ 5) ЛИМИТЕД filed Critical ВАЙВ ХЕЛТКЕР ЮКей (№ 5) ЛИМИТЕД
Publication of EA201890361A1 publication Critical patent/EA201890361A1/ru
Publication of EA033057B1 publication Critical patent/EA033057B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Раскрыты соединения формулы I, включая фармацевтически приемлемые соли, фармацевтические композиции, содержащие соединения, способы получения соединений и их применение в ингибировании интегразы ВИЧ и лечении инфицированных ВИЧ или СПИД. В соединениях формулы I Rвыбран из водорода, алкила или циклоалкила; Rвыбран из тетрагидроизохинолинила и замещен одним заместителем Rи дополнительно 0-3 галогеновыми или алкильными заместителями; Rвыбран из азетидинила, пирролидинила, пиперидинила, пиперазинила, морфолинила, гомопиперидинила, гомопиперазинила или гомоморфолинила и замещен 0-3 заместителями, выбранными из циано, галогена, алкила, галогеналкила, алкокси и галогеналкокси; Rвыбран из алкила или галогеналкила; Rпредставляет собой алкил; Rвыбран из Ar, (Ar)алкила, (хроманил)алкила, цианоциклоалкила или (дигидробензодиоксинил)алкила; Arпредставляет собой фенил, замещенный 0-5 заместителями, выбранными из циано, галогена, алкила, циклоалкила, галогеналкила, гидрокси, алкокси, галогеналкокси, (гидрокси)алкокси, (алкокси)алкокси, фенокси, бензилокси, карбокси, фенила и цианоциклоалкила.
EA201890361A 2015-08-11 2016-08-10 Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека EA033057B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562203791P 2015-08-11 2015-08-11
PCT/IB2016/054832 WO2017025917A1 (en) 2015-08-11 2016-08-10 5-(n-benzyl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
EA201890361A1 EA201890361A1 (ru) 2018-11-30
EA033057B1 true EA033057B1 (ru) 2019-08-30

Family

ID=56851651

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890361A EA033057B1 (ru) 2015-08-11 2016-08-10 Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека

Country Status (23)

Country Link
US (2) US10189816B2 (ru)
EP (1) EP3334716A1 (ru)
JP (1) JP6782766B2 (ru)
KR (1) KR20180032649A (ru)
CN (1) CN108137534A (ru)
AR (1) AR105653A1 (ru)
AU (1) AU2016306089B2 (ru)
CA (1) CA2994791A1 (ru)
CL (1) CL2018000363A1 (ru)
CO (1) CO2018001359A2 (ru)
CR (1) CR20180091A (ru)
DO (1) DOP2018000035A (ru)
EA (1) EA033057B1 (ru)
HK (1) HK1249503A1 (ru)
IL (1) IL257240B (ru)
MA (1) MA42614A (ru)
MX (1) MX2018001722A (ru)
PE (1) PE20181002A1 (ru)
PH (1) PH12018500294A1 (ru)
TW (1) TWI657086B (ru)
UA (1) UA120464C2 (ru)
WO (1) WO2017025917A1 (ru)
ZA (1) ZA201800689B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522913A (ja) * 2015-08-12 2018-08-16 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−［６，５］−縮合二環式アリールテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体
TW201718537A (zh) * 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
JP2019515003A (ja) * 2016-05-11 2019-06-06 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
EP3455214A1 (en) * 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US20200325127A1 (en) * 2016-05-11 2020-10-15 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201835068A (zh) * 2017-01-03 2018-10-01 英商Viiv醫療保健英國(No.5)有限公司 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物
JP2020503352A (ja) * 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010130034A1 (en) * 2009-05-15 2010-11-18 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2015126726A1 (en) * 2014-02-20 2015-08-27 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2015127003A1 (en) * 2014-02-20 2015-08-27 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2220095B1 (en) 2007-11-15 2013-01-02 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
JP5269086B2 (ja) * 2007-11-15 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
UA100250C2 (ru) 2007-11-16 2012-12-10 Гілеад Сайнсіз, Інк. Ингибиторы репликации вируса иммунодефицита человека
EP2220084B1 (en) 2007-11-16 2014-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
SG10201408512RA (en) 2009-12-23 2015-02-27 Univ Leuven Kath Novel antiviral compounds
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9580431B2 (en) 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2014159959A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JP2018522913A (ja) * 2015-08-12 2018-08-16 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−［６，５］−縮合二環式アリールテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体
TW201718537A (zh) * 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
CA2995087A1 (en) * 2015-08-12 2017-02-16 John F. Kadow 5-(n-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010130034A1 (en) * 2009-05-15 2010-11-18 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2015126726A1 (en) * 2014-02-20 2015-08-27 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2015127003A1 (en) * 2014-02-20 2015-08-27 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBERTO DI SANTO: "Inhibiting the HIV Integration Process: Past, Present, and the Future", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 57, no. 3, 13 February 2014 (2014-02-13), pages 539 - 566, XP055207945, ISSN: 00222623, DOI: 10.1021/jm400674a *

Also Published As

Publication number Publication date
CR20180091A (es) 2018-06-13
HK1249503A1 (zh) 2018-11-02
AU2016306089A1 (en) 2018-03-01
JP2018522927A (ja) 2018-08-16
ZA201800689B (en) 2021-08-25
EP3334716A1 (en) 2018-06-20
UA120464C2 (uk) 2019-12-10
PE20181002A1 (es) 2018-06-26
US10189816B2 (en) 2019-01-29
CN108137534A (zh) 2018-06-08
AR105653A1 (es) 2017-10-25
AU2016306089B2 (en) 2018-08-09
DOP2018000035A (es) 2018-03-30
US20190092754A1 (en) 2019-03-28
CO2018001359A2 (es) 2018-05-10
KR20180032649A (ko) 2018-03-30
MA42614A (fr) 2021-05-26
CL2018000363A1 (es) 2018-07-06
IL257240A (en) 2018-03-29
IL257240B (en) 2020-02-27
EA201890361A1 (ru) 2018-11-30
TW201718549A (zh) 2017-06-01
JP6782766B2 (ja) 2020-11-11
PH12018500294A1 (en) 2018-08-13
MX2018001722A (es) 2018-05-16
TWI657086B (zh) 2019-04-21
WO2017025917A1 (en) 2017-02-16
CA2994791A1 (en) 2017-02-16
US20180230129A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
EA033057B1 (ru) Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
MX2020010737A (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12016500723B1 (en) Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SG10201805033XA (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MD4800C1 (ru) Соединения аминопиримидинила в качестве ингибиторов JAK
MX2020011810A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
MY174042A (en) Fused bicyclic sulfamoyl derivative and the use thereof as medicaments for the treatment of hepatitis b.
MX353412B (es) Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
AR099511A1 (es) Derivados del ácido piridin-3-ilacético como inhibidores de la replicación del virus de inmunodeficiencia humana
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
MX366123B (es) Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b.
MX2015015771A (es) Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b.
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2019012945A (es) Formas cristalinas de un compuesto inhibidor de jak.
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
TN2016000511A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
JP2017526748A5 (ru)
MX2018011283A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer.
AU2012360910A8 (en) Quinazolinone derivatives as HCV inhibitors
WO2015198263A3 (en) Novel betulinic proline substituted derivatives as hiv inhibitors
MX2018014165A (es) Compuestos heterociclicos utiles como agentes antibacterianos y metodo de produccion.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU